MindRank doses first patient in Phase III trial of AI-designed oral GLP-1 agonist MDR-001

MindRank announced it has dosed the first patient in a Phase III trial of MDR-001, an oral GLP-1 receptor agonist designed using the company's AI platforms. The company says the program used its PharmKG knowledge graph, Molecule Dance protein simulation, and Molecule Pro generative AI with ADMET prediction alongside wet‑lab validation.

MindRank announced dosing of the first patient in a Phase III trial of MDR-001, an oral GLP-1 receptor agonist designed with artificial intelligence. The company characterized the dosing as a major milestone for the program and for AI-enabled drug development. MindRank described multiple internal platforms used in the program, including a biological knowledge graph and protein simulation tools. The development also combined generative AI, ADMET prediction, and iterative laboratory validation. Key details: - The first patient has been dosed in the Phase III study of MDR-001, an AI-designed oral GLP-1 receptor agonist. - Zhangming Niu, MindRank Founder and CEO, described the dosing as a major milestone for the program and for AI-enabled drug development. - MDR-001 was developed using the PharmKG biological knowledge graph to integrate literature and pathway analysis. - The team used Molecule Dance for protein dynamic simulation and to analyze GPCR binding conformation and signal transduction. - Design work included quantification of cAMP agonism and biased β-arrestin 2 recruitment to guide selectivity. - The Molecule Pro platform's generative AI and ADMET prediction modules were applied alongside wet‑lab iterative feedback to inform druggability and safety considerations. Summary: The announcement frames the first-patient dosing as a development milestone and highlights the use of multiple AI-driven platforms across discovery and optimization. Details about the Phase III trial timeline, endpoints, and next procedural steps were not provided. Undetermined at this time.